EIC Accelerator Challenge: Novel biomarker-based assays to guide personalised cancer treatment
Programme Category
Programme Name
Programme Description
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Identifier Code
Call
Summary
This EIC Accelerator Challenge aims to improve the efficacy, safety and uptake of therapeutic approaches against refractory cancers, using novel comprehensive predictive, prognostic and companion diagnostic tests, in the context of precision oncology.
The overall goal of this Challenge is to support and accelerate the preclinical validation and/or clinical phase 1 work carried out by innovative SMEs (including start-ups, spinouts) and small midcaps to develop novel predictive, prognostic and companion diagnostic assays to guide cancer treatment.
Detailed Call Description
This Challenge has the following specific objectives:
- to develop novel companion diagnostic assays, including through liquid profiling to identify who, among cancer patients, is more likely to benefit from a given treatment (guided treatment);
- to develop novel predictive biomarker-based assays to identify who, among patients with potentially precancerous lesions, is more likely to develop cancer;
- to develop novel prognostic assays including through liquid profiling to identify who, among the cancer patients who underwent treatment, is more likely to recur;
- to develop novel companion diagnostic assays, including through liquid profiling to identify who, among the cancer patients receiving treatment, is more likely to develop side effects as a result of the treatment and,
- to develop novel monitoring biomarker-based assays to effectively monitor the clinical course of the disease.
As expected outcomes from this Challenge, clinicians will be able to:
- Identify, who among cancer patients, is more likely to benefit from a given treatment (guided treatment),
- Identify, who among patients with potentially precancerous lesions, is more likely to develop cancer,
- Identify, who among the cancer patients having underwent treatment, is more likely to recur,
- Identify who among the cancer patients receiving treatment, is more likely to develop side effects as a result of the treatment, affecting their quality of life and
- More effectively monitor the clinical course of the disease.
Call Total Budget
Thematic Categories
- Health
- Research, Technological Development and Innovation
- Small-Medium Enterprises and Competitiveness
Eligibility for Participation
- Researchers/Research Centers/Institutions
- Small and Medium Enterprises (SMEs)
Eligibility For Participation Notes
To be an eligible applicant to EIC Accelerator, you must apply as one of the following eligible entities:
- a single company classified as a SME and established within a Member State or an Associated Country (see Annex 2 of the EIC Work Programme 2023); or
- a single company classified as a small mid-cap (up to 499 employees) established in a Member State or an Associated Country, but only for exceptional cases for rapid scale up purposes ; or
- One or more natural persons (including individual entrepreneurs) or legal entities, which are either:
a. From a Member State or an Associated Country intending to establish an SME or small mid-cap (as defined above) in a Member State or Associated Country by the time of signing the EIC Accelerator contract or, in case the equity only is awarded, at the latest when agreeing on its investment component;
b. Intending to invest in an SME or small mid-cap in a Member State or an Associated Country and who may submit a proposal on behalf of that SME or small mid-cap, provided that a prior agreement exist with the company. The contract will be signed with the beneficiary company only; or
c. From a non-associated third country intending to establish an SME (including start-ups) or to relocate an existing SME to a Member State or an Associated Country. Your company must prove its effective establishment in a Member State or an Associated Country at the time of submission of the full proposal.
Applicants from the United Kingdom can apply to the EIC Accelerator, but can only request and receive funding in the form of “grant only”. The signature of any grant agreement will be subject to the positive conclusion of the association negotiation with the United Kingdom.
Call Opening Date
Call Closing Date
National Contact Point(s)
Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia,
P.B. 23422, 1683 Nicosia
Telephone: +357 22205000
Fax: +357 22205001
Email: support@research.org.cy
Website: https://www.research.org.cy/en/
Contact Persons:
George Christou
Scientific Officer
Email: gchristou@research.org.cy
Nedi Kaffa
Scientific Officer
Email: nkaffa@research.org.cy
EU Contact Point
Research Enquiry Service: https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en